Atlas Venture Life Science Advisors, LLC Dyne Therapeutics, Inc. Transaction History
Atlas Venture Life Science Advisors, LLC
- $455 Million
- Q2 2025
A detailed history of Atlas Venture Life Science Advisors, LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Atlas Venture Life Science Advisors, LLC holds 9,130,465 shares of DYN stock, worth $159 Million. This represents 19.12% of its overall portfolio holdings.
Number of Shares
9,130,465
Previous 9,130,465
-0.0%
Holding current value
$159 Million
Previous $95.5 Million
8.99%
% of portfolio
19.12%
Previous 27.97%
Shares
6 transactions
Others Institutions Holding DYN
# of Institutions
212Shares Held
125MCall Options Held
36.5KPut Options Held
74.3K-
Vanguard Group Inc Valley Forge, PA9.76MShares$170 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA9.71MShares$169 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$165 Million0.05% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$129 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$95.3 Million14.09% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $903M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...